Enasidenib Market Size and Growth Forecast: Global Insights and Analysis
Report ID : 1315798 | Published : May 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Enasidenib Market is categorized based on Drug Type (Monotherapy, Combination Therapy) and Indication (Acute Myeloid Leukemia (AML), Other Hematological Malignancies) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
As of 2023, the Enasidenib Market size stood at $500 million and is expected to attain $1.2 billion by 2033, growing at a 9.0% CAGR from 2024 through 2033. The report includes diverse segments and offers an analysis of trends and factors substantially impacting the market.
The market for Enasidenib is changing quite fast, due to the cases of acute myeloid leukemia (AML) disease emerging and the popularity for targeted therapies. IDH2 mutations have been linked to Enasidenib, a small-molecule inhibitor, which is now a vital resin in the treatment of relapsed or refractory AML Directed patients. More and more healthcare professionals and patients are embracing a new concept which targets mutated isocitrate dehydrogenase 2 (IDH2) and inhibits it.
Verified Industry Insights is a full-service market research company and examines the intricacies of the Enasidenib Market including analysis of the market’s trends, competition and regulatory activities that affect the direction of the market. Our reports aim B2B markets and provide good opportunities for pharmaceutical companies, healthcare providers, and investors who are focusing on the complementary but quite prospective therapeutic area. With regard to market and patient needs, we help our clients with making appropriate strategic choices.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | Agios Pharmaceuticals, Celgene Corporation, Bristol-Myers Squibb, Novartis AG, Pfizer Inc., Roche Holding AG, Amgen Inc., Merck & Co. Inc., AstraZeneca plc, Gilead Sciences Inc., Eli Lilly and Company |
| SEGMENTS COVERED |
By Drug Type - Monotherapy, Combination Therapy
By Indication - Acute Myeloid Leukemia (AML), Other Hematological Malignancies
By Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Enasidenib Market Dynamics
The Enasidenib Market is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Enasidenib Market Segmentations
Market Breakup by Drug Type
- Overview
- Monotherapy
- Combination Therapy
Market Breakup by Indication
- Overview
- Acute Myeloid Leukemia (AML)
- Other Hematological Malignancies
Market Breakup by Distribution Channel
- Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Enasidenib Market
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- Agios Pharmaceuticals
- Celgene Corporation
- Bristol-Myers Squibb
- Novartis AG
- Pfizer Inc.
- Roche Holding AG
- Amgen Inc.
- Merck & Co. Inc.
- AstraZeneca plc
- Gilead Sciences Inc.
- Eli Lilly and Company
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved